Icosapent ethyl for the treatment of hypertriglyceridemia

Bibliography

• Miller M, Stone NJ, Ballantyne C, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011;123:2292-333
   PubMed Web of Science ®Google Scholar
• Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011;13:544-52
   PubMedGoogle Scholar
• Cohen JD, Cziraky MJ, Cai Q, 30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006. Am J Cardiol 2010;106:969-75
   PubMed Web of Science ®Google Scholar
• Ford ES, Li C, Zhao G, Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med 2009;169:572-8
   PubMedGoogle Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Lovaza [package insert]. GlaxoSmithKline; Research Triangle Park, NC: 2012
   Google Scholar
• Vascepa [package insert]. Amarin Pharma, Inc; Bedminster, NJ: 2012
   Google Scholar
• Fruchart JC, Sacks FM, Hermans MP, The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008;5:319-35
   PubMed Web of Science ®Google Scholar
• Fletcher B, Berra K, Ades P, Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112:3184-209
   PubMed Web of Science ®Google Scholar
• Ono K. Current concept of reverse cholesterol transport and novel strategy for atheroprotection. J Cardiol 2012;60:339-43
   PubMed Web of Science ®Google Scholar
• Niaspan [package insert]. Abbott Laboratories; North Chicago, IL: 2010
   Google Scholar
• Kostner K, Gupta S. Niacin: a lipid polypill? Expert Opin Pharmacother 2008;9:2911-20
   PubMed Web of Science ®Google Scholar
• Brooks EL, Kuvin JT, Karas RH. Niacin's role in the statin era. Expert Opin Pharmacother 2010;11:2291-300
   PubMed Web of Science ®Google Scholar
• Schima SM, Maciejewski SR, Hilleman DE, Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opin Pharmacother 2010;11:731-8
   PubMed Web of Science ®Google Scholar
• Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother 2011;12:1429-38
   PubMed Web of Science ®Google Scholar
• Tricor [package insert]. Abbott Laboratories; North Chicago, IL, 2010
   Google Scholar
• Juxtapid [package insert]. Aegerion Pharmaceuticals, Inc; Cambridge, MA: 2012
   Google Scholar
• Rizzo M. Lomitapide, a microsomal triglyceride transfer protein inhibitor for the treatment of hypercholesterolemia. IDrugs 2010;13:103-11
   PubMed Web of Science ®Google Scholar
• Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des 2011;17:943-9
   PubMed Web of Science ®Google Scholar
• Zargar A, Ito MK. Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database. Metab Syndr Relat Disord 2011;9:255-71
   PubMed Web of Science ®Google Scholar
• Collins N, Tighe AP, Brunton SA, Differences between dietary supplement and prescription drug omega-3 fatty acid formulations: a legislative and regulatory perspective. J Am Coll Nutr 2008;27:659-66
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Overview of dietary supplements. Food and Drug Administration. 2009. Available from: http://www.fda.gov/Food/DietarySupplements/ConsumerInformation/ucm110417.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=dietary [Last accessed 26 April 2012]
   Google Scholar
• Fish oil and omega-3 fatty acid supplements (EPA and DHA from fish, algae, and krill). Consumer Lab. 2012. Available from: https://www.consumerlab.com/reviews/fish_oil_supplements_review/omega3/ [Last accessed 4 May 2012]
   Google Scholar
• FDA announces qualified health claims for omega-3 fatty acids. Food and Drug Administration. 2009. Available from: http://www.fda.gov/SiteIndex/ucm108351.htm [Last accessed 12 September 2012]
   Google Scholar
• Skulas-Ray AC, West SG, Davidson MH, Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Expert Opin Pharmacother 2008;9:1237-48
   PubMed Web of Science ®Google Scholar
• Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep 2011;13:474-83
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Glickstein SB, Rowe JD, Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J Clin Lipidol 2012;6:5-18
   PubMed Web of Science ®Google Scholar
• Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57
   PubMed Web of Science ®Google Scholar
• Tatsuno I, Saito Y, Kudou K, Efficacy and safety of TAK-085 in comparison with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the Omega-3 fatty acids Randomized Double-blind (ORD) study. J Clin Lipidol 2013; In press
   Google Scholar
• Harris WS, Ginsberg HN, Arunakul N, Safety and efficacy of omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997;4:385-91
   PubMedGoogle Scholar
• Pownall HJ, Brauchi D, Kilinc C, Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 1999;143:285-97
   PubMed Web of Science ®Google Scholar
• Nettleton JA. Omega-3 fatty acids and health. Springer (formerly Chapman & Hall); New York, NY: 1995
   Google Scholar
• Davidson MH, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol 2011;22:437-44
   PubMed Web of Science ®Google Scholar
• Bays HE, Tighe AP, Sadovsky R, Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008;6:391-409
   PubMedGoogle Scholar
• Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387-93
   PubMed Web of Science ®Google Scholar
• Bays H. Fish oils in the treatment of dyslipidemia and cardiovascular disease. In: Kwiterovich PO, editor. The Johns Hopkins textbook of dyslipidemia. Lippincott Williams & Wolters Kluwer; Philadelphia, PA; 2010. p. 245-57
   Google Scholar
• Braeckman RA, Manku MS, Bays HE, Effects of AMR101, a pure EPA omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in patients with very high triglycerides (results from the MARINE trial) [abstract]. Eur Heart J 2011;32(Suppl 1):510-11
   Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol 2011;108:682-90
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Braeckman RA, Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs 2013;13:37-46
   PubMed Web of Science ®Google Scholar
• Bays HE, Braeckman RA, Ballantyne CM, Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). J Clin Lipidol 2012;6:565-72
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-22
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol 2012;110:984-92
   PubMed Web of Science ®Google Scholar
• Brinton EA, Ballantyne CM, Bays HE, Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract 629-P]. Diabetes 2012;61(Suppl 1):A159-60
   Google Scholar
• Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C-43C
   PubMed Web of Science ®Google Scholar
• Brunton S, Collins N. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr Med Res Opin 2007;23:1139-45
   PubMed Web of Science ®Google Scholar
• Weitz D, Weintraub H, Fisher E, Fish oil for the treatment of cardiovascular disease. Cardiol Rev 2010;18:258-63
   PubMed Web of Science ®Google Scholar
• Substances affirmed as generally recognized as safe: menhaden oil. Fed Regist 2005;70:14530-2
   Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
   PubMed Web of Science ®Google Scholar
• Epadel [package insert]. Mochida Pharmaceutical Co, Ltd, Tokyo, Japan; 2007
   Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
   PubMed Web of Science ®Google Scholar
• Merck announces HPS2-THRIVE study of TREDAPTIVE™ (extended-release niacin/laropiprant) did not achieve primary endpoint. Merck & Co., Inc. 2012. Available from: http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-announces-hps2-thrive-study-tredaptive-extended-relea [Last accessed 6 February 2013]
   Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26
   PubMed Web of Science ®Google Scholar
• Rauch B, Schiele R, Schneider S, OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-9
   PubMed Web of Science ®Google Scholar
• ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-18
   PubMed Web of Science ®Google Scholar
• A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin (REDUCE-IT). 2012. Available from: http://clinicaltrials.gov/show/NCT01492361 [Last accessed 6 February 2013]
   Google Scholar